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Advances have been made in treatment and outcomes for pediatric cancer. However adolescents and young adults (AYAs) with
cancer have not experienced similar relative improvements. We undertook a study to develop the methodology necessary for
epidemiologic cancer research in these age groups. Our goal was to create the Kids, Adolescents, and Young Adults Cancer
(KAYAC) project to create a resource to address research questions relevant to this population. We used a combination of clinic
and population-based ascertainment to enroll 111 cases aged 0–39 for this methodology development study. The largest groups
of cancer types enrolled include: breast cancer, leukemia, lymphoma, and melanoma. The overall participation rate is 69.8% and
varies by age and tumor type. The study included patients, mothers, and fathers. The methods used to establish this resource are
described, and the values of the resource in studies of childhood and young adult cancer are outlined.
Copyright © 2009 Nancy J. Link et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Childhood, adolescent, and young adult cancers are among
the “rare cancers” and consequently very few epidemio-
logic studies are carried out to address research questions
related to etiology, clinical outcome, and disparities in this
group of patients (0–39 years of age). Further, studies
of adolescent and young adult (AYA) cancer (age 15–
39) are less frequent compared to studies of childhood
cancer (0–14 years). Multiple reasons may account for this
deﬁciency including: (1) low incidence rates particularly
in certain cancers; (2) diﬃculties in obtaining and assess-
ing risk factor information especially in young patients;
(3) lack of standardized health care access for AYA patients;
(4) diagnosis and treatment often rendered by pediatric or
adult oncologists rather than AYA specialized oncologists;
(5) lack of fully developed methodology for these age groups
[1, 2].
It is clear that the mortality rate due to cancer in
children, adolescents, and young adults is variable by age,
even within the same type of cancer. In addition, adolescents
and young adults are at a higher risk for diﬀerent types of
cancers compared to younger children, such as lymphomas,
bone tumors, and soft-tissue sarcomas [3]. The disparity
that results from these diﬀerences is particularly seen by
race/ethnicity, in terms of the cancer diagnosis, access to
treatment, eligibility for the same clinical trials and care [4].
In 2006 the National Cancer Institute (NCI) and the
Lance Armstrong Foundation convened a Progress Review
Group (PRG) of experts in the area of Adolescent and
Young Adult Oncology (AYAO) and issued a report describ-
ing the research and care imperatives for cancer in the
AYA population [1]. While signiﬁcant advances have been
made in treatment and outcomes for pediatric patients,
the PRG reported that AYAs have not experienced similar
relative improvements [1]. Several interrelated factors may2 Journal of Cancer Epidemiology
contribute to the lack of improvement in early detection,
diagnosis,treatment,outcome,andfollow-upcareincluding:
(a) lack of reliable data and deﬁciency of research speciﬁc
for the AYA population, (b) increased sense of personal
invincibility prevalent in the AYA population that inﬂuences
their clinical outcomes, (c) low suspicion of cancer diagnosis
in this age group by health providers, (d) a lack of adequate
health insurance (AYAs) (have the highest uninsured rate of
any age group in the US) [5], (e) lack of primary care and
oncology infrastructure focused speciﬁcally on AYA health,
and (f) poor understanding of patient and tumor biology.
In addition AYAs are rarely referred to the few clinical trials
available for their age group which can result in use of
treatment protocols that have not been speciﬁcally tested in
adolescent or young adult cancer cases [3, 4].
The PRG identiﬁed ﬁve research and care imperatives
for improving the outcomes of adolescents and young adults
with cancer, one of which described the need to create
the tools necessary to study the AYA cancer problem in
particular to (1) create a prospective database on all AYA
cancer patients, (2) increase the number of annotated tumor,
normal tissue, and other biospecimens, and (3) create or
modify assessment tools speciﬁc to AYA cancer issues [1, 6].
In response to the PRG recommendations, we under-
took a study to develop the methodology necessary for
epidemiologic studies of cancer in these age groups and
included children aged 0–14 to allow for comparisons of the
experience between childhood and AYA participants and to
oﬀer recommendations for future epidemiologic studies in
these age groups.
The research goal of KAYAC is to develop protocols
and collect risk factor and clinical data and biospecimens
from kids, adolescents, and young adults with cancer to be
used to investigate: (a) whether adolescent and young adult
cancers are diﬀerent from childhood and older adult cancers
with respect to speciﬁc genetic susceptibility to exposures,
etiologic risk factors, and whether they can be characterized
using biological markers; (b) the degree of aggressiveness
of cancer in adolescents and young adults and the cancer
outcome in AYA patients; (c) examine barriers to health care
accessusingquestionnairedatacollectedfromAYAsandtheir
parents. This resource is envisioned to be used in future
studies for planning cancer prevention and control in this
unique population.
2.MaterialsandMethods
2.1. Study Design and Protocol. We developed the study
protocolasoutlinedinFigure 1.After protocol development,
Institutional Review Board approval was obtained at UC
Irvine (HS# 2006-4958) and CHOC Children’s Hospital
(IRB# 070538).
Three versions of study questionnaires were developed
using previously validated questions; one each for cases,
mothers and fathers. Questionnaires were pilot tested,
and ﬁnalized versions were deployed into the ﬁeld. Items
included in the questionnaires were designed to obtain data
from the parents on exposures up to 1 year preconception,
during pregnancy and after birth to the date of diagnosis.
We also collected risk factor information, family history
of cancer as well as health history information from the
case and their parents. Additional questionnaire items
included immunization and general environmental expo-
sures, residential history, parental occupational exposures,
and a psychosocial needs assessment. Family cancer history
information was also used to generate picture pedigrees
and veriﬁcation tables that were mailed to subjects for
conﬁrmation and corrections.
In addition to questionnaire data, clinical variables
were also obtained from the cancer registry such as date
of diagnosis, tumor information (site, histology, behavior,
and diﬀerentiation), disease stage, and treatment history.
Demographic variables were collected from both the cancer
registry and the study questionnaires. Linkage with the
population-based cancer registry provides valuable follow-
up information including vital status, subsequent primary
tumor diagnoses, date of last follow-up or death, and cause
of death. Table 1 provides a summary of collected data items.
The questionnaires used are available upon request.
For cases with no mother or father available, we inter-
viewed legally authorized representatives (LARs). In some
cases, where only the mother or the father was available,
we interviewed one parent in addition to the cancer patient
(over age 15). For children under age 15, the parent/LAR
completed the patient questionnaire on the case’s behalf.
Blood samples were collected from patients (aged 0–14) at
the pediatric clinic and from their parent(s)/LAR at their
convenience, at the clinic by hospital staﬀ or home by a
certiﬁed phlebotomist. For patients aged 15–39 and their
parent(s)/LAR, blood was collected either in their home or
at our research facility. Participants and/or parents living
outside of the three-county recruitment area were sent
a kit containing appropriate specimen tubes and speciﬁc
instructions for a laboratory or doctor’s oﬃce to collect
the sample and return to us by overnight delivery mail
using provided prepaid shipping labels and packaging. All
bloodsamplesreceivedbarcodelabelsbeforebeingprocessed
in the Department of Epidemiology laboratory, where all
barcodelabeledaliquotsweretrackedusingtheKAYACstudy
database.
2.2. Eligibility. Eligible patients were those diagnosed with
cancer between 1/1/2006 and 6/30/2008 and their par-
ents/LAR. Patients were ascertained through the population-
based cancer registry. Patients below age 15 were ﬁrst
contacted through collaboration with the CHOC Children’s
Hospital. Patients between 15 and 39 were contacted using
information from the cancer registry. For all patients the
methodology below was used by the study staﬀ in the UCI
Epidemiology Department.
2.3. Ascertainment and Recruitment
2.3.1. Childhood Cases Aged 0–14. Patients and their par-
ent(s)/LAR were approached by a physician or other clinic
staﬀ during the patient’s regular clinic visit and they wereJournal of Cancer Epidemiology 3
Eligibility criteria:
Diagnosed with 1st primary cancer in Orange,
San Diego and imperial counties
from 1/1/2006–6/30/2009
Males and females, age 0–39
Population-based ascertainment (AYA)
• Patients identiﬁed through California
cancer registry (CCR)
• Sent letter of introduction
Clinic-based ascertainment (kids)
• Patients seen at hospital clinic
• Case and/or parents/LAR
approached by hospital staﬀ
Recruitment
• Follow-up call made by research interviewer to answer questions and invite
participation (up to ﬁve telephone attempts)
• Interview and biospecimen collection appointments scheduled with willing participants
• Verbal consent obtained prior to questionnaire interview
• AYA patients invite parents for participation
Datacollection
• Questionnaire completed and entered into CGRIS database
• Picture pedigree and veriﬁcation table printed for the patients’ family history of cancer
and sent for conﬁrmation and correction
• Consent signature obtained prior to biospecimen collection
• Blood sample collected by phlebotomist, MD, nurse, or laboratory at the convenience of patient.
Figure 1: Study protocol.
invited to participate. If they were willing to participate,
the clinic staﬀ asked that the parent sign their approval for
contact information to be provided to the KAYAC research
oﬃce. Upon receipt of the signed contact information sheet,
the Epidemiology Department study recruiter contacted
the family, described the study including eligibility criteria,
research procedures, and length of time required to complete
participation and scheduled a time and place for the inter-
viewand blood draw forthe parents.Patients werescheduled
for blood draw during a regular clinic appointment. We
developed and applied this protocol in the recruitment of 44
patients as a pilot study. Descriptive data on these 44 patients
is presented in Table 2.
2.3.2. Adolescent and Young Adult Cases Aged 15–39. Eligible
patients were mailed a recruitment packet which included
a letter of introduction that brieﬂy described the study,
eligibility criteria, research procedures, and estimated length
of time required to complete participation. Also included
in the packet were the KAYAC study brochure and a con-
tact/interest reply form with a postage-paid return envelope.
By using the contact/interest reply form, subjects were able
to provide their preferred method of contact (i.e., email,
home, or mobile phone), best day and time to reach them,
or to decline participation. Two weeks after packets were
mailed, an interviewer contacted the patient by telephone
to answer any questions, and if the patient was willing,
enroll them in the study. Those with Spanish surnames were
mailed recruitment packet materials in both English and
Spanish and contacted by a bilingual research associate. One
or both parents/LAR of willing participants were recruited
for study participation by invitation from the case. If the
parent(s)/LAR agreed to participate, a KAYAC interviewer
completed the enrollment protocol. We developed this
protocol and applied it in the recruitment of 82 patients as a
pilot study. Descriptive data on these 82 patients is presented
in Table 2.
2.3.3. Detailed Contact Procedures for All Participants, Aged
0–39 Years. Up to ﬁve telephone attempts were made to
contact each subject. A telephone “attempt” included leaving
a message with a household member, leaving a voicemail
message, or calling without leaving a message. After ﬁve
telephone attempts resulting in no direct contact with the
subject, a second recruitment packet was mailed. If all
recruitment attempts proved to be unsuccessful, the subject
ﬁle was closed and coded as unable to contact (UTC).
Interviewers bilingual in English and Spanish were available
to conduct all recruitment and research procedures.
Allstudyparticipantswereassigneduniqueidentiﬁcation
numbers (family and member IDs) upon ascertainment.
The study ID numbers were used on all study documents,
database tracking screens, and biospecimen samples to
ensure conﬁdentiality of patient information. Subject per-
sonal identiﬁers are never included in analysis, reporting, or
publications. Participants and parents were assured that they4 Journal of Cancer Epidemiology
Table 1: Representative sample of variables collected in KAYAC case and parent questionnaires.
Case (birth–early
childhood) Case Case (at
diagnosis) Mother Mother
Prenatal Father Father
Prenatal
Extended
family
Demographics
Race/ethnicity X X X X
Marital status X X X
Date of birth X X X X X
Date of death (if applicable) X X X
Religious aﬃliation X X X X
Birthplace X X X X
Cancer information
History of cancer X X X X
Cancer type and histology X X X X
Date/age of diagnosis X X X X
Hospital of diagnosis X X X X
Social and economic status (SES)
Education X X X X
Health insurance X X X
Income X X (household)
Risks, exposures, general health
General Health and Illnesses X X X X X X X
Height and weight X X X X X
Immunizations X X X
Medications and vitamins taken X X X X X X
Pesticide and chemical exposure X X X X X X
Radiation/X-ray exposure X X X
Animal exposure X X
International travel X
Occupational history X X X X X
T o b a c c o u s e X XXXX X
Alcohol use X X
Breastfeeding X
Reproductive history X X X
Other
Psychological/emotional well-being X
Social support X
Quality of life X
could refuse to participate in the study or in any portion
of the study at any time without jeopardizing their medical
care.
2.4. Data and Biospecimen Processing. Participant electronic
data including biospecimen and subject tracking, question-
naire, and family cancer history information, were entered
into the research database previously developed by the UCI
Department of Epidemiology: the Cancer Genetic Research
Information System (CGRIS). To protect the conﬁdentiality
of research participants, this central informatics system
includes use of encryption software, a ﬁrewall system,
password requirements for access, storage of conﬁdential
information in separate extract ﬁles, and study reporting
systemthatcontainsnoconﬁdentialinformation.Participant
paperresearchﬁlesarestoredinalargemedicalrecordsroom
with controlled access behind locked doors and passkey
protected entry.
Blood samples were barcode labeled prior to being
processed into serum, plasma, red blood cells, DNA, lym-
phocytes, and buﬀyc o a t sa n ds t o r e di n−80
◦Co r−140
◦C
freezers. All sample aliquots received a barcode label that
was scanned into the CGRIS biospecimen tracking database
and identiﬁes the location of where the specimens are stored
allowing for future retrieval and links each specimen to
corresponding subject data.Journal of Cancer Epidemiology 5
Table 2: Participation by subject type.
Children (age 0–14) AYA (age 15–39)
Total ascertained and agreed to be contacted 44 Total ascertained and contact was attempted 218
Participated in the study 29 Participated in the study 82
Agreed to be contacted but later declined participation 15 Unable to contact 87
—— Contacts were made but patient declined participation 33
Deceased 16
Participation rate 65.9% Participation rate (excluding deceased and UTC) 71.3%
Parents
Number of invited eligible parents 215
Participated in the study 135
Declined participation 46
Deceased 9
No permission given by the patient to
contact the parent
25
Participation rate (excluding deceased) 65.5%
3. Results andDiscussion
3.1. Childhood Cases Aged 0–14. As is shown in Table 2,
in collaboration with the children’s hospital we ascertained
44 childhood cancer cases whose parents agreed to be
contacted by the study team for enrollment in the study. We
determined that the invitation to participate be presented
ﬁrst to the patient and their family by the physician in
order to increase the likelihood of participation and to
ensure that any questions that parents may have about their
child’s participation would be answered by the child’s doctor.
This method of engaging the physician in the KAYAC study
recruitment has been very successful and it increased our
ability to obtain support and approval of the attending
physicians.
To date 29 childhood cancer patients and one or both of
their parents have participated by completing questionnaires
and donating blood samples. It is of note that parents of
an additional 15 patients who initially agreed to participate
subsequently decided against participation at the time of
contact by the research associate however, these families
may decide to join the study in the future. The change
in willingness to participate may be inﬂuenced by their
child’s clinical condition or by other factors including
emotional burden or time commitments. To date, the overall
participation rate for this age group is 65.9%. Demographic
distributions for the 29 participants are included in Table 3.
There were equal numbers of males and females and a
majority (55.2%) were Hispanic (Table 3). Figure 2 describes
the distribution of patients by cancer type. The majority of
the patients have leukemia, a total of 25 of whom 17 partici-
pated for a participation rate of 68%. The participation rate
for lymphoma was 80% and was lower for brain cancer and
sarcoma; however there were a very small number of these
cases.
3.2. Adolescent and Young Adult (AYA) Cases Aged 15–39. A
total of 82 AYA cases were enrolled in the KAYAC study. The
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Figure 2: (a) Participation rate by cancer type for pediatric
population(age0–14).(b)Participationratebycancer typeforAYA
population (age 15–39).
cancer-type distribution of the 82 enrolled cases is shown
in Figure 2. The most common cancer types for AYA cases
enrolled in the study were breast, leukemia, lymphoma, and
melanoma.6 Journal of Cancer Epidemiology
Table 3: Patient Demographics.
Children 0–14 years old AYA 15–39 years old
(n = 29) (n = 82)
Sex No. % Sex No. %
male 15 51.7% male 27 32.9%
female 14 48.3% female 55 67.0%
Age Age
0–5 8 27.6% 15–19 6 7.3%
6–10 10 34.5% 20–24 12 14.6%
11–14 11 37.9% 25–29 23 28.0%
30-34 14 17.0%
34-39 27 32.9%
Race/Ethnicity Race/ethnicity
Non-Hispanic white 8 26.6% Non-Hispanic white 53 64.6%
Hispanic 16 55.2% Hispanic 23 28.0%
Asian 5 17.2% Asian 6 7.3%
Of 218 AYA cases identiﬁed as eligible in the cancer
registry, 82 enrolled in KAYAC, yielding a 71.3% participa-
tion rate (Table 2) among a population often assumed to be
diﬃcult to access and reluctant to participate in research [7].
As shown in Figure 2, the cancer type with the highest rate of
participation for the AYA group is breast (85%) followed by
lymphoma (82%) and leukemia (75%).
We believe that these participation rates are excellent for
epidemiologic studies in AYA and encouraging for future
applicationtocancerepidemiologicstudiesinthisagegroup.
The participation rate for parents was 65% (Table 2). As
described in the methods above we contacted the parent or
parents only with permission of the AYA patient, and only
after they have had an opportunity to describe the study to
the parent(s). Of interest, permission was not granted by
the patient to contact their parent(s) for 25 of 215 parents,
although in these instances the patient participated fully in
the study (Table 2). Characteristics of the AYA participants
are included in Table 3. As evident, 2/3 of this group
was females and the majority were non-Hispanic whites
(64.6%).
4. Conclusion andFutureDirections
The KAYAC study was established to address methodologic
issues in the recruitment and participation of childhood,
adolescent, and young adult cancer patients into epidemi-
ologic studies that will promote research in this age group.
Because there has been little patient-contact research con-
ducted on this age range, the KAYAC project was intended to
demonstrate the feasibility of ascertaining cases, establishing
contact, and collecting data. The majority of AYA cases who
agreed to participate in the study expressed both enthusiasm
and interest in the research eﬀort. Through KAYAC we
have created an infrastructure by which future clinical and
epidemiologic studies speciﬁc to cancer patients between 0
a n d3 9y e a r so l dw i l lb ec o n d u c t e d .
Strengths of the KAYAC study include the population-
based ascertainment of cases and high participation rates
of the common cancer types. Cancer registry linkage facil-
i t a t e so u t c o m em e a s u r e sa sf o l l o w - u pi n f o r m a t i o nm a yb e
obtained for years to come. Enrollment of parents of cases
also allows for validation of some exposures which are
assessed through both case and parent questionnaires and
for exposure assessments during pre- and peri-natal periods.
Thus, the KAYAC study allows for classiﬁcation of cases in
terms of a broad range of lifetime exposures.
Because the KAYAC resource is population based, adoles-
cents and young adults as well as early onset breast cancer
are represented. It is important to note that this resource
has the potential to oﬀer an in depth investigation into
the uniqueness of very early onset breast cancer, as well
as the heterogeneity of characteristics, etiology, and disease
progression which would be important in tailoring breast
cancer prevention and control in speciﬁc age groups.
The establishment of a data and biorepository designed
to study cancer in kids, adolescents, and young adults has
presented some challenges. Locating AYA participants was
often diﬃcult and time-consuming. While the participation
rate of those for whom we had accurate contact information
was quite high, of 218 cancer-registry ascertained AYA
cases, 87 had inaccurate contact information and were
classiﬁed as unable to contact (UTC). This could be due
to several reasons, including the high mobility of this
age group and diﬃculty in updating contact information.
Even when an eligible case with contact information was
identiﬁed, the eﬀorts needed to locate, reach, and enroll
them can be extensive. For the 82 AYA participants enrolled,
numerous contact attempts (by phone and/or mail) were
needed to obtain each individual’s initial consent, schedule
and conduct the interview and biospecimen collection.
Additionally, while one of the strengths of our project is
its minority representation and the inclusion of Spanish
speakers, using bilingual interviewers and translated study
documents increased study complexity and costs.Journal of Cancer Epidemiology 7
Creating and maintaining the infrastructure required to
support and sustain the KAYAC study requires a wide variety
of study personnel. The study leaders include epidemiolo-
gists and an oncologist specializing in pediatric, adolescent,
and young adult cancer care. Other needed staﬀ members
include research associates, a phlebotomist, a data manager,
interviewers (including at least one bilingual interviewer), a
statistician, and laboratory personnel.
The KAYAC project is an example of the development
of an infrastructure and a resource of children and young
adults with cancer and their parents for future studies.
We anticipate future collaborative associations with other
investigators on studies related to pediatric, adolescent and
youngadultcancer.Broadcategoriesofresearchprojectsthat
may be facilitated or supported by this resource include the
following.
(i) Investigations of biologic characteristics (such as
genetic and tumor factors) of pediatric and AYA
cancers that aﬀect disease outcome (including sur-
vival, treatment response, second primary cancer,
and quality of life).
(ii) Assessmentoftheavailabilityandaccesstohealthcare
facilities that can enroll members of these age groups
into clinical trials and determine possible barriers to
access to healthcare by these patients.
(iii) Development of protocols to determine the degree
of aggressiveness of cancer among the age groups
included in KAYAC.
(iv) Determination of epidemiologic and environmental
risk factors including family history and presence of
suspect chemicals in the home environment.
(v) Development of a health literacy campaign and
outreach for patients and parents.
(vi) Examination of epidemiologic characteristics (such
as demographic, socioeconomic, treatment, lifestyle,
pre- and peri-natal and environmental exposures)
of pediatric and AYA patients that aﬀect disease
outcome (including survival, treatment response,
second primary cancer, and quality of life).
In conclusion, the establishment of the KAYAC study has
proven to be feasible and the participation rate of this age
group was shown to be excellent. KAYAC will serve as a
resource to advance knowledge and understanding of cancer
incidence and outcome among this underserved group.
Knowledge of the biologic, environmental, and lifestyle
factors which contribute to disease progression, response
to treatment, and prognosis will inform the development
of targeted treatment interventions aimed at improving
outcomes among this unique and vital segment of our
population.
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